Scholarlink

Purpose <p>To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer’s recommended induction phase of treatment.</p> Methods <p>Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.</p> Results <p>Thirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm<sup>3</sup> (−19.66%; <i>p</i> = 0.0164), sample standard deviation (ssd) = 0.114 mm<sup>3</sup>), mean height (mean decrease of 0.00871 mm (−19.16%; <i>p</i> = 0.0003), ssd = 0.0143 mm), and maximum height (mean decrease of 0.0242 mm (−15.28%; <i>p</i> = 0.002), ssd = 0.0359). Significant decreases in MNV metrics were also observed, including area (mean decrease of 0.252 mm<sup>2</sup> (−9.06%; <i>p</i> = 0.0054), ssd = 0.519 mm<sup>2</sup>), and vessel area density (mean decrease of 6.51% absolute (−8.23%; <i>p</i> = 0.0004), ssd = 0.0943% absolute). BCVA (logMAR) remained stable between baseline and 3 months (0.25–0.23; <i>p</i> = 0.34). Notably, there were no statistically significant changes in the percentage of eyes with intraretinal fluid (IRF) or subretinal fluid (SRF) between baseline and 3 months (all <i>p</i> &gt; 0.05).</p> Conclusions <p>In recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD

  • 期刊论文

  • 发表日期：

    2025年1月25日

查看全文
  • Arnold Nadel,
  • Michael Drakopoulos,
  • Harnaina K. Bains,
  • Avram Bar-Meir,
  • Alessandro Marchese,
  • Alice T. Lyon,
  • Rukhsana G. Mirza

摘要

Purpose

To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer’s recommended induction phase of treatment.

Methods

Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.

Results

Thirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm3 (−19.66%; p = 0.0164), sample standard deviation (ssd) = 0.114 mm3), mean height (mean decrease of 0.00871 mm (−19.16%; p = 0.0003), ssd = 0.0143 mm), and maximum height (mean decrease of 0.0242 mm (−15.28%; p = 0.002), ssd = 0.0359). Significant decreases in MNV metrics were also observed, including area (mean decrease of 0.252 mm2 (−9.06%; p = 0.0054), ssd = 0.519 mm2), and vessel area density (mean decrease of 6.51% absolute (−8.23%; p = 0.0004), ssd = 0.0943% absolute). BCVA (logMAR) remained stable between baseline and 3 months (0.25–0.23; p = 0.34). Notably, there were no statistically significant changes in the percentage of eyes with intraretinal fluid (IRF) or subretinal fluid (SRF) between baseline and 3 months (all p > 0.05).

Conclusions

In recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.